
    
      75 subjects at risk for HIV infection (25 high risk MSM and 50 sero-discordant couples) will
      be recruited. All subjects will receive Truvada for PrEP, as well as routine medical
      evaluations during one year. Subjects will be managed according to CDC's guidelines on the
      management of PrEP as a tool for HIV prevention.

      All subjects will have a total of at least 8 study visits during which routine assessment are
      performed for patients on Truvada for PrEP. Apart from offering routine medical care, a
      baseline questionnaire that includes socio-demographic variables, PrEP knowledge and
      acceptability and sexual conducts will be offered. At the 6 months visit, an abbreviated
      sexual conducts questionnaire will be offered.
    
  